New treatment for a serious brain condition called ADEM
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
['FUNDING_OTHER'] · TRETHERA CORPORATION · NIH-10896386
This study is testing a new drug called TRE-515 to help children with a serious condition called acute disseminated encephalomyelitis (ADEM) by blocking a specific enzyme that causes harmful immune responses, with the hope of improving their recovery.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TRETHERA CORPORATION (nih funded) |
| Locations | 1 site (SHERMAN OAKS, UNITED STATES) |
| Trial ID | NIH-10896386 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new small molecule drug, TRE-515, aimed at treating acute disseminated encephalomyelitis (ADEM), a severe autoimmune disease primarily affecting children. The approach involves inhibiting a specific enzyme, deoxycytidine kinase (dCK), which plays a crucial role in the proliferation of immune cells that attack the nervous system. By blocking this enzyme, the treatment aims to reduce harmful immune responses and improve recovery outcomes for patients suffering from ADEM. The research includes preclinical studies using a mouse model to evaluate the drug's effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with acute disseminated encephalomyelitis (ADEM).
Not a fit: Patients with ADEM who are already receiving corticosteroid treatments or those with other underlying conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a targeted therapy for ADEM, potentially improving recovery rates and reducing the side effects associated with current corticosteroid treatments.
How similar studies have performed: While there is ongoing research into treatments for ADEM, the specific approach of using TRE-515 to inhibit dCK is novel and has not been extensively tested in clinical settings.
Where this research is happening
SHERMAN OAKS, UNITED STATES
- TRETHERA CORPORATION — SHERMAN OAKS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHULTZ, KENNETH — TRETHERA CORPORATION
- Study coordinator: SCHULTZ, KENNETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.